- Details
- In a detailed discussion between Pedro Barata and Camillo Porta, they dissect the findings from the update of the CLEAR study. The study explores the effectiveness of lenvatinib and pembrolizumab versus sunitinib in treating advanced renal cell carcinoma patients. The results revealed significantly higher medium progression-free survival and overall survival rates for the lenvatinib/pembrolizumab...
|
- Details
- In this discussion, Pedro Barata and Nizar Tannir focus on the PIVOT-09 Phase III trial. They delve into the potential and challenges of the experimental combination treatment, bempegaldesleukin (BEMPEG) plus nivolumab, which showed promising initial results but was terminated due to disappointing trial outcomes. Despite this, Dr. Tannir remains optimistic about the Interleukin 2 (IL-2) pathway, p...
|
- Details
- In this conversation, Pedro Barata and Andrea Apolo highlight an exploratory analysis of the CheckMate 9ER trial in patients with previously untreated advanced renal cell carcinoma (aRCC), looking at the association between depth of response and clinical outcomes with extended follow-up (minimum 25.4 months; median 32.9 months). In January 2021, the Food and Drug Administration (FDA) approved the...
|
- Details
- Alicia Morgans interviews Toni Choueiri to discuss key topics related to kidney cancer. They delve into strategies for treating metastatic kidney cancer, focusing on combined and sequential drug approaches. Dr. Choueiri elaborates on failures and successes, particularly regarding the use of three drugs simultaneously and the importance of managing toxicity. They also discuss treatment for patients...
|
- Details
- Thomas Powles discusses the results of the CALYPSO trial with Pedro Barata. Dr. Powles provides an overview of the trial design of this international, multicentre, open-label phase Ib/IIa study of durvalumab alone, savolitinib alone, and durvalumab in combination with savolitinib or tremelimumab in patients with metastatic renal cell cancer. He then discusses the trial results, plus his thoughts o...
|
- Details
- Deepak Kilari joins Pedro Barata in a discussion on the ORACLE study, which investigates the efficacy of combination systemic therapies in patients with advanced non-clear cell renal cell carcinoma. Dr. Kilari gives an overview of the trial design and shares his hopes and goals for the future of this trial as it continues to expand to more institutions and provide a larger, more robust data set. B...
|
- Details
- Pedro Barata and Nizar Tannir explore updated findings from the CheckMate 214 study, with a focus on sarcomatoid renal cell carcinoma (RCC) patients. They note that despite an improvement in patient outcomes due to nivolumab/ipilimumab (nivo/ipi) treatment, 20% of patients still progress, underscoring the need for ongoing research. The study showed significantly improved response rates and overall...
|
- Details
- Pedro Barata and Hans Hammers discuss a significant paper published in JCO, detailing a phase II trial with nivolumab for treatment of advanced clear cell Renal Cell Carcinoma (RCC). Dr. Hammers attributes the conception of the study to Dr. Mike Atkins and the trials primarily focus on nivolumab's effectiveness in various risk groups. The trials were designed to adopt a risk-adaptive approach, sta...
|
- Details
- Pedro Barata hosts Nizar Tannir to discuss the CANTATA trial for advanced renal cell carcinoma (RCC) treatment. Dr. Tannir explicates the historical progression of RCC therapies, emphasizing the biological implications of glucose metabolism in tumor cells and the need for alternative energy sources such as glutamine. Telaglenastat, a glutaminase inhibitor, offers a potential breakthrough, disrupti...
|
- Details
- In this conversation, Pedro Barata hosts Toni Choueiri to discuss a significant paper that he published on the CheckMate 9ER trial, which has established the combination of cabozantinib-nivolumab as a new standard of care for patients with advanced renal cell carcinoma. The extended follow-up analysis of about 33 months showed statistically significant and clinically relevant progression-free surv...
|
